S-Ketamine vs R-Ketamine: The Real Differences in Effects and Experience

When my psychiatrist offered me ketamine treatment last year, I did what I usually do and went down a Reddit rabbit hole. Within a week I was neck-deep in threads debating S-ketamine versus R-ketamine as if they were rival sports teams. One camp swore R-ketamine was the future. Another said Spravato was the only legitimate option. Academic papers I could barely read seemed to say both and neither. I ended up more confused than when I started. If you have found yourself trying to make sense of the same online debates and wondering what the actual difference is between S-ketamine and R-ketamine, this blog post walks you through what each one does, what the research really shows, and what it means for the treatment you may be considering.

What S-Ketamine and R-Ketamine Actually Are

Understanding S-ketamine and R-ketamine starts with understanding that they are not different drugs. They are two forms of the same molecule that mirror each other, like a right hand and a left hand. Both are "ketamine." Neither is "better than ketamine." Getting this foundational picture straight is what makes the rest of the science make sense.

Here is what you need to know:

The molecular difference (mirror-image molecules)

Ketamine molecules can exist in two forms called enantiomers. S-ketamine (also called esketamine) is the "left-handed" version. R-ketamine (also called arketamine) is the "right-handed" version. They have identical chemical compositions but their atoms are arranged in opposite three-dimensional orientations. Like a right hand does not fit into a left glove, S and R can bind differently to certain proteins in the brain even though they are chemically the same substance.

What "racemic ketamine" means

The traditional ketamine that has been used medically since the 1960s is a racemic mixture, meaning it contains a 50/50 blend of S-ketamine and R-ketamine. When your doctor talks about "regular ketamine" or "IV ketamine" for depression, they are almost always talking about the racemic form. Both enantiomers are working in your body at the same time.

Which one you are getting in different treatments

Spravato (the FDA-approved nasal spray) is pure S-ketamine only. IV, intramuscular (IM), and sublingual ketamine protocols use racemic ketamine, meaning you are getting both S and R together. R-ketamine on its own is not commercially available in the U.S., though it is being studied in ongoing clinical trials.

The Real Differences in How They Work in the Brain

The two enantiomers act on some of the same brain systems but engage them differently, which produces meaningfully different effects downstream. This is where the research gets interesting because the story does not always follow the pattern you would expect. Understanding the mechanism helps make sense of the counterintuitive findings that come up later.

Here is what the research shows:

NMDA receptor binding (S is significantly stronger)

The NMDA receptor is the primary molecular target for ketamine's rapid effects. S-ketamine binds NMDA receptors roughly three to four times more strongly than R-ketamine does. This higher potency is one reason S-ketamine produces stronger acute effects at lower doses. It is also the reason S-ketamine has more anesthetic potency, and part of the reason it produces more dissociation.

BDNF and neuroplasticity (R may actually be stronger here)

BDNF stands for brain-derived neurotrophic factor, a protein that supports the growth of new neural connections. This is the pathway most researchers think produces ketamine's antidepressant effects. Interestingly, animal studies suggest R-ketamine produces stronger and more sustained BDNF activation than S-ketamine does. R-ketamine also appears to promote more synaptogenesis (formation of new synapses) in the prefrontal cortex and hippocampus, brain regions closely tied to mood.

The unique features of R-ketamine

R-ketamine appears to activate additional pathways that S-ketamine does not. It engages sigma-1 receptors, affects microglia through TGF-beta-1 signaling, and appears to influence the gut microbiome-brain axis. These pathways may explain why R-ketamine can produce robust antidepressant effects despite binding NMDA receptors more weakly than S-ketamine. The full mechanism is still being mapped in ongoing research.

The Real Differences in Antidepressant Effects

This is where the story gets counterintuitive. You would expect the enantiomer that binds more strongly (S-ketamine) to be the stronger antidepressant. The animal research consistently suggests the opposite. Understanding this paradox helps explain why R-ketamine has generated so much research interest despite its weaker NMDA binding. Here is what the studies actually show:

What the research shows about effectiveness

Multiple studies in animal models of depression show that R-ketamine produces greater and longer-lasting antidepressant-like effects than S-ketamine. A landmark 2015 Nature Translational Psychiatry paper by Yang and colleagues demonstrated that R-ketamine had greater potency and longer duration in social defeat stress and learned helplessness models. Subsequent research has confirmed this pattern.

How long the effects last (R appears longer)

Beyond potency, R-ketamine appears to produce more sustained effects. Animal studies suggest R-ketamine's antidepressant benefits last longer per dose than S-ketamine's. This may be partly explained by R-ketamine's stronger effect on BDNF signaling and synaptogenesis, which produce longer-lasting neural changes than acute NMDA blockade alone.

The surprising R > S finding in animal studies

The order of antidepressant strength in animal studies is generally R-ketamine > racemic ketamine > S-ketamine. The order of side effects is generally reversed: S-ketamine > racemic ketamine > R-ketamine. This is a genuinely surprising pattern that has driven much of the recent research interest in R-ketamine. It should also be noted that these findings come from animal models and small human studies. Larger controlled trials in humans are ongoing but not yet complete.

The Real Differences in Side Effects and Experience

The subjective and side-effect differences between the two enantiomers matter as much as the antidepressant effects, because they shape whether someone can tolerate treatment. For patients sensitive to dissociation, these differences can determine whether they can continue treatment at all. Here is how the two compare on the experience side:

Dissociation (S causes significantly more)

S-ketamine produces more intense dissociative experiences than R-ketamine, particularly at doses used for depression treatment. For deeper detail on how these acute effects show up during a session, what a ketamine session actually feels like walks through the sensory experience. The dissociation is not necessarily bad. Some patients find it therapeutically valuable. Others find it uncomfortable or frightening. Individual preference matters a lot here.

Psychotomimetic effects (S more, R minimal)

Psychotomimetic effects are the psychosis-mimicking effects that ketamine can produce at higher doses, including altered thought patterns, perceptual changes, and paranoid feelings. S-ketamine produces significantly more of these than R-ketamine. Studies in healthy volunteers suggest R-ketamine may not produce psychotomimetic effects at all at therapeutic antidepressant doses.

Abuse potential (S higher, R lower)

S-ketamine appears to have higher abuse potential than R-ketamine. This is one reason Spravato is delivered only in certified clinics under a Risk Evaluation and Mitigation Strategy (REMS) protocol. R-ketamine research suggests significantly lower abuse liability, though this remains under investigation.

What each feels like subjectively

Racemic ketamine (containing both enantiomers) produces the "traditional" ketamine experience most people associate with the treatment. Pure S-ketamine tends to produce a more intense, more clearly dissociative experience with less subtle emotional layering. Pure R-ketamine, in the limited human trials so far, tends to produce a gentler, less dissociative experience that some patients describe as feeling more like a mood shift than an altered state.

FDA Status and What You Can Actually Access

For all the interesting research on R-ketamine, there is a practical question that matters more than the science for anyone considering treatment: what can you actually get right now? The answer depends on where you live and which form of ketamine you are considering. Here is the current state of access in 2026:

S-ketamine (Spravato) is FDA-approved and available

Spravato was FDA-approved in March 2019 for treatment-resistant depression and later for major depressive disorder with acute suicidal ideation. It is delivered only through certified clinics under REMS requirements. Because it is FDA-approved for these specific indications, most insurance plans cover it when patients meet the criteria. Practices offering Spravato through certified programs are typically the most affordable ketamine option for patients with treatment-resistant depression.

R-ketamine is in clinical trials, not commercially available

R-ketamine is undergoing clinical trials in the U.S. and internationally. As of 2026, it is not commercially available for prescription. Patients interested in R-ketamine specifically can look for clinical trials through ClinicalTrials.gov, though enrollment criteria are typically strict.

Racemic ketamine (containing both) is used off-label

The traditional racemic ketamine form (containing both S and R together) is widely used off-label for depression, anxiety, and other conditions through IV infusion, IM injection, and sublingual lozenge protocols. It is not FDA-approved for these psychiatric uses, so insurance typically does not cover it, but it is legally prescribed by trained clinicians across the U.S.

Which Type Actually Fits Your Situation

The decision about which type of ketamine treatment fits your situation is not usually a decision about which enantiomer is theoretically best. It is a decision about what you can access, what your insurance covers, and how your body responds to different formulations. Understanding how ketamine is administered across different methods fills out the practical side of this decision.

Here is a real framework:

If you have treatment-resistant depression

Spravato (pure S-ketamine) is FDA-approved for treatment-resistant depression and typically covered by insurance. It is often the most cost-effective starting point. If you can tolerate the dissociation and the two-hour monitoring window, Spravato is worth considering first because the insurance math usually works out better than off-label options.

If you are sensitive to dissociation or side effects

If you have tried Spravato and found the dissociation intolerable, or if you have concerns about intense psychotomimetic effects, racemic ketamine at lower doses may produce a gentler experience because it contains both enantiomers rather than pure S-ketamine. R-ketamine may eventually offer an even gentler option once it becomes available.

If cost or insurance is the primary constraint

Insurance-covered Spravato is often the lowest out-of-pocket cost even though the retail price per session is highest. Off-label racemic ketamine has lower retail cost per session but rarely gets insurance coverage. Sublingual lozenges through supervised telehealth are typically the least expensive option overall.

How to talk to your prescriber about your options

Ask your prescriber which forms of ketamine they can offer, how they choose between them for different patients, and what the practical differences look like for your specific situation. A good prescriber has clear reasons for recommending one form over another based on your medical history, insurance situation, and personal preferences rather than only what their clinic happens to offer.

Working With Massachusetts Mind Center

At Massachusetts Mind Center we provide ketamine treatment in the Boston area, including intramuscular and sublingual lozenge protocols using racemic ketamine (which contains both S and R together) plus Spravato (pure S-ketamine) through our certified program for patients with FDA-approved indications. Because we offer both forms, we can be genuinely honest about which one fits your specific situation rather than defaulting to whatever we happen to have available. Our team handles the medical screening, session support, and integration therapy so all parts of the process work together rather than separately. Call 617-236-2193 and a real person will help you figure out the right starting point.

Frequently Asked Questions

What is the difference between esketamine and arketamine? 

Esketamine is another name for S-ketamine (the "left-handed" enantiomer). Arketamine is another name for R-ketamine (the "right-handed" enantiomer). They are two mirror-image forms of the same molecule that make up traditional racemic ketamine when combined 50/50. Esketamine is the active ingredient in Spravato.

Is R-ketamine available for treatment? 

Not currently in the U.S. as of 2026. R-ketamine is being studied in clinical trials but is not commercially available for prescription. If you are specifically interested in R-ketamine, ClinicalTrials.gov lists ongoing studies you may be able to enroll in.

Which is better for depression, S-ketamine or R-ketamine? 

Animal studies consistently suggest R-ketamine produces stronger and longer-lasting antidepressant effects with fewer side effects. However, the human data on R-ketamine is still limited, and S-ketamine (as Spravato) has established FDA-approved effectiveness. The practical answer is usually "the one you can actually access," which is currently S-ketamine or racemic ketamine.

Does racemic ketamine give you the benefits of both enantiomers? 

Yes. Racemic ketamine contains both S and R, meaning you receive both sets of effects. Some researchers argue this is why racemic ketamine appears to have better antidepressant outcomes than pure S-ketamine (Spravato) in some studies. The R portion may contribute meaningful antidepressant benefit even though it is not the target of Spravato specifically.

Does Spravato feel different from IV ketamine? 

Yes. Spravato is pure S-ketamine and tends to produce a more intense, clearly dissociative experience per unit dose. IV ketamine is racemic and contains both enantiomers, which many patients describe as producing a subtly different quality of experience with slightly less pronounced dissociation for comparable clinical effect. Individual response varies significantly.